|Bid||142.49 x 100|
|Ask||143.74 x 1000|
|Day's Range||142.33 - 144.00|
|52 Week Range||96.93 - 144.00|
|PE Ratio (TTM)||44.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Will the good times keep rolling for Abeona Therapeutics, BeiGene, and Vanda Pharmaceuticals?
Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend. Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice. If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it.
With the market grinding higher, some breakouts struggle. But Apple, Microsoft, Biogen, Alexion Pharmaceuticals, Wynn Resorts and Electronic Arts are holding in buy zones after breaking out several days or weeks ago.